SW · SDZ.SW
Sandoz Group AG
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Rotkreuz 6343
- Website
- sandoz.com
Price · as of 2024-12-31
$62.54
Market cap 29.12B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $28.90 | -53.79% |
| Intrinsic Value(DCF) | $84.82 | +35.63% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $8.50 | $17.20 | |||
| 2022 | $0.00 | $8.20 | |||
| 2023 | $26.91 | $31.96 | $5.24 | $2.40 | $3.40 |
| 2024 | $38.13 | $36.14 | $1.90 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Sandoz Group AG's (SDZ.SW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $28.90
- Current price
- $62.54
- AI upside
- -53.79%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$84.82
+35.63% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
- CEO
- Richard Saynor
- Employees
- 22.05K
- Beta
- 0.26
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($84.82 ÷ $62.54) − 1 = +35.63% (DCF, example).